HOME >> MEDICINE >> NEWS
Even in an era of HAART Drugs, HIV patients are vulnerable to opportunistic infections

line therapy. They may not be effective, however, in patients who have previously had treatment with this class of drugs. Patients who are responding to HAART may be doing well enough that they don't need prophylaxis, she said.

"The risks versus benefits must be carefully evaluated. We want to protect patients from MAC, but we also want to prevent them from developing resistance to antibiotics," said Aberg, who is a UCSF assistant professor of medicine and also treats patients at San Francisco General.

In the pre-HAART era, macrolides were standard treatment as prevention therapy against MAC infection in AIDS patients whose CD4+ counts were below 75, according to Aberg. Now with HAART, many patients may have CD4+ counts that are higher.

The main conclusion from study findings, she said, is that careful consideration should be given to continuing use of macrolides for MAC prophylaxis when CD4+ counts have increased and to using macrolides for infection treatment if a patient has been on a macrolide previously.

Both research studies were supported by grants from the NIH UCSF Center for AIDS Research and the UC Universitywide AIDS Research Program,

In addition, the CMV retinitis study received a grant from Research to Prevent Blindness, Inc., and the macrolide bacterial resistance study received support from Abbott Laboratories.


'"/>

Contact: Corinna Kaarlela
ckaarlela@pubaff.ucsf.edu
415-476-3804
University of California - San Francisco
27-Sep-1999


Page: 1 2 3

Related medicine news :

1. Most episodes of HIV blips not clinically significant in patients receiving HAART
2. Multiple characteristics of HAART affect adherence
3. Researchers examine the use of antiretroviral therapy among injection drug users with HIV infection: Study suggests addiction treatment and health care contribute to HAART enrollment
4. ICAAC highlight: MAC prophylaxis can be safely discontinued in HIV-infected patients who respond to HAART
5. Old Drugs, New Tricks
6. Hormonal treatment improves survival in high-risk prostate cancer patients
7. Study finds that coordinating care of chronically ill patients does not increase liability
8. Mouse model reveals potential way to reduce cardiac deaths in kidney patients
9. Optical technique identifies vulnerable plaques in cardiac patients
10. NHS target driven culture is failing patients
11. Cardiac deaths peak in sleep hours for patients with sleep apnea

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/16/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... Director of its Sienna Plantation facility. , “We are pleased to announce Dr. ... Dr. Michael (Derek) Caraway, Area Medical Director of First Choice Emergency Room – North ...
(Date:8/16/2017)... ... ... Break Every Chain”: an inspirational story for those shackled by the chains of a broken ... Shivers, a writer and a woman of great faith and wisdom. She is a ... She was born and raised in Vero Beach, Florida and has dedicated her life and ...
(Date:8/15/2017)... Buffalo, NY (PRWEB) , ... August 15, 2017 , ... ... as maintenance treatment for multiple myeloma has been completed, with the team’s findings now ... Philip L. McCarthy, MD , Director of the Blood and Marrow Transplant Program at ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading dental ... the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The Tampa ... who has shown three consecutive years of growth. For this year’s award, Progressive Dental ...
(Date:8/15/2017)... ... 2017 , ... Dr. Timothy Davis is now administering two ... This information can be used to develop patient-specific treatment plans for periodontal disease ... tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® Labs, Inc., a subsidiary ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Flight Network and PeaceHealth Oregon Network announced they renewed a ... efficiency for patients at hospitals in Eugene ... , and Florence, Oregon , who ... work collaboratively to move patients who require the highest level ... emergency exists. PeaceHealth ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
(Date:7/31/2017)... , July 31, 2017 Three Tru-D SmartUVC ... South Korea . Tru-D, short for "Total Room Ultraviolet ... operating rooms after an environmental services (ES) professional cleans the area with ... ... "Although the BAACH ...
Breaking Medicine Technology:
Cached News: